Journal article
Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
Abstract
Purpose of ReviewOral tyrosine kinase inhibitors have revolutionized the treatment of chronic myelogenous leukemia, with many patients achieving major clinical and molecular responses without complications. While typically well-tolerated, clinical experience with tyrosine kinase inhibitors (particularly those of the second and third generations) has highlighted unanticipated associations with serious non-cancer adverse effects on various …
Authors
Gustafson D; Fish JE; Lipton JH; Aghel N
Journal
Current Hematologic Malignancy Reports, Vol. 15, No. 1, pp. 20–30
Publisher
Springer Nature
Publication Date
February 2020
DOI
10.1007/s11899-020-00560-x
ISSN
1558-8211